Product: c-Met Mouse Monoclonal Antibody
Catalog: BF8218
Description: Mouse monoclonal antibody to c-Met
Application: WB
Reactivity: Human, Mouse, Monkey
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 145kDa; 156kD(Calculated).
Uniprot: P08581

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Mouse
Application:
WB 1:500-1:3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Monkey
Clonality:
Monoclonal [AFfirm8218]
Specificity:
c-Met Antibody detects endogenous levels of total c-Met.
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AUTS9; c met; D249; Hepatocyte growth factor receptor; HGF; HGF receptor; HGF/SF receptor; HGFR; MET; Met proto oncogene tyrosine kinase; MET proto oncogene, receptor tyrosine kinase; Met proto-oncogene (hepatocyte growth factor receptor); Met proto-oncogene; Met protooncogene; MET_HUMAN; Oncogene MET; Par4; Proto-oncogene c-Met; RCCP2; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P08581 MET_HUMAN:

Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. Expressed in metaphyseal bone (at protein level) (PubMed:26637977).

Description:
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.
Sequence:
MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS

PTMs - P08581 As Substrate

Site PTM Type Enzyme
T17 Phosphorylation
K85 Ubiquitination
N106 N-Glycosylation
S178 Phosphorylation
K189 Ubiquitination
K223 Ubiquitination
K324 Ubiquitination
K376 Ubiquitination
S468 Phosphorylation
S473 Phosphorylation
S637 Phosphorylation
S641 Phosphorylation
K725 Ubiquitination
Y745 Phosphorylation
T750 Phosphorylation
K751 Ubiquitination
S755 Phosphorylation
S758 Phosphorylation
T759 Phosphorylation
K765 Ubiquitination
Y830 Phosphorylation
K876 Ubiquitination
K962 Ubiquitination
S966 Phosphorylation
Y971 Phosphorylation
T977 Phosphorylation
S985 Phosphorylation Q02156 (PRKCE) , P17252 (PRKCA) , Q05655 (PRKCD)
S988 Phosphorylation
S990 Phosphorylation
T992 Phosphorylation
T993 Phosphorylation
S997 Phosphorylation
S1000 Phosphorylation
Y1003 Phosphorylation
T1006 Phosphorylation
S1016 Phosphorylation
S1020 Phosphorylation
Y1026 Phosphorylation
Y1093 Phosphorylation
T1096 Phosphorylation
K1103 Ubiquitination
K1104 Ubiquitination
K1110 Ubiquitination
Y1159 Phosphorylation
K1161 Ubiquitination
K1179 Ubiquitination
K1190 Acetylation
K1190 Ubiquitination
K1193 Ubiquitination
Y1194 Phosphorylation
K1199 Ubiquitination
K1215 Ubiquitination
K1219 Ubiquitination
Y1230 Phosphorylation P08581 (MET)
K1232 Ubiquitination
Y1234 Phosphorylation P08581 (MET) , Q04912 (MST1R)
Y1235 Phosphorylation P08581 (MET) , P51813 (BMX) , Q04912 (MST1R)
S1236 Phosphorylation
K1240 Ubiquitination
T1241 Phosphorylation
K1244 Ubiquitination
K1248 Ubiquitination
K1259 Ubiquitination
T1289 Phosphorylation
Y1307 Phosphorylation
Y1313 Phosphorylation
K1318 Ubiquitination
S1342 Phosphorylation
T1343 Phosphorylation
Y1349 Phosphorylation P00519 (ABL1) , Q04912 (MST1R) , P08581 (MET)
T1355 Phosphorylation
Y1356 Phosphorylation P00519 (ABL1) , Q04912 (MST1R) , P08581 (MET)
Y1365 Phosphorylation P08581 (MET)
S1367 Phosphorylation
S1370 Phosphorylation
S1371 Phosphorylation

PTMs - P08581 As Enzyme

Substrate Site Source
P08581-1 (MET) T977 Uniprot
P08581-1 (MET) S988 Uniprot
P08581-1 (MET) S990 Uniprot
P08581 (MET) Y1230 Uniprot
P08581 (MET) Y1234 Uniprot
P08581 (MET) Y1235 Uniprot
P08581 (MET) Y1349 Uniprot
P08581 (MET) Y1356 Uniprot
P08581 (MET) Y1365 Uniprot
P09874 (PARP1) Y907 Uniprot
P29353 (SHC1) Y427 Uniprot
Q04912 (MST1R) Y1238 Uniprot
Q04912 (MST1R) Y1239 Uniprot
Q04912 (MST1R) Y1353 Uniprot
Q04912 (MST1R) Y1360 Uniprot
Q05397 (PTK2) Y5 Uniprot
Q05397 (PTK2) Y194 Uniprot
Q05397 (PTK2) Y397 Uniprot
Q05397 (PTK2) Y407 Uniprot
Q05397 (PTK2) Y576 Uniprot
Q05397 (PTK2) Y577 Uniprot
Q05397 (PTK2) Y861 Uniprot
Q05397 (PTK2) Y925 Uniprot
Q13480-1 (GAB1) Y285 Uniprot
Q13480 (GAB1) Y307 Uniprot
Q13480 (GAB1) Y373 Uniprot
Q13480-1 (GAB1) Y406 Uniprot
Q13480-2 (GAB1) Y447 Uniprot
Q13480 (GAB1) Y472 Uniprot
Q13480 (GAB1) Y589 Uniprot
Q13480-2 (GAB1) Y619 Uniprot
Q13480-1 (GAB1) Y627 Uniprot
Q13480-2 (GAB1) Y657 Uniprot
Q13480-1 (GAB1) Y659 Uniprot
Q13480-2 (GAB1) Y689 Uniprot

Research Backgrounds

Function:

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).

(Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells.

PTMs:

Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2.

Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis, resulting in decreasing plasma membrane receptor abundance, and in endosomal degradation and/or recycling of internalized receptors.

(Microbial infection) Tyrosine phosphorylation is stimulated by L.monocytogenes InlB. Tyrosine phosphorylation is maximal 10-20 minutes after treatment with InlB and disappears by 60 minutes. The phosphorylated residues were not identified.

Subcellular Location:

Membrane>Single-pass type I membrane protein.

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. Expressed in metaphyseal bone (at protein level).

Subunit Structure:

Heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when phosphorylated with downstream effectors including STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1, SPSB2 and SPSB4 (By similarity). Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction. Interacts with MUC20; prevents interaction with GRB2 and suppresses hepatocyte growth factor-induced cell proliferation. Interacts with GRB10. Interacts with PTPN1 and PTPN2. Interacts with LECT2; this interaction may have an antagonistic effect on receptor activation. Interacts with HSP90AA1 and HSP90AB1; the interaction suppresses MET kinase activity.

(Microbial infection) Interacts via extracytoplasmic residues 25-656 with L.monocytogenes InlB; MET can bind HGF, its endogenous ligand, and InlB simultaneously. InlB probably dimerizes upon binding to MET, which encourages subsequent dimerization of MET (Probable).

Family&Domains:

The kinase domain is involved in SPSB1 binding.

The beta-propeller Sema domain mediates binding to HGF.

Belongs to the protein kinase superfamily. Tyr protein kinase family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Organismal Systems > Development > Axon guidance.   (View pathway)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.